In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its ...

Back in May 2025, dapiglutide failed to impress in a phase 2 trial, mustering up to an average 4.3% reduction in weight loss when given at the 6 mg dose. The 54-person study involved administering ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

While the previous PATHFINDER study—a prospective, year-long examination of about 6,600 people—showed that Galleri could more ...

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...

Against an increasingly uncertain market backdrop, industry analysts EY said they are keeping an eye on potential ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

A pair of professional organizations in the U.K. is calling for the biopharma industry and national government to take action ...